Genmab A/S(GMAB)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

GMAB Genmab A/S

盘前交易 02-13 08:40:49 EST

29.59

-0.47

-1.56%

盘前29.80

+0.21+0.71%

08:30 EST

最高30.17	最低29.47	成交量137.26万
今开30.05	昨收30.06	日振幅2.33%
总市值182.27亿	流通市值179.91亿	总股本6.16亿
成交额4,083万	换手率0.23%	流通股本6.08亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"GMAB","market":"US","secType":"STK","nameCN":"Genmab A/S","latestPrice":29.59,"timestamp":1770930000000,"preClose":30.06,"halted":0,"volume":1372551,"hourTrading":{"tag":"盘前","latestPrice":29.8,"preClose":29.59,"latestTime":"08:30 EST","volume":8130,"amount":242091.99369,"timestamp":1770989406378,"change":0.21,"changeRate":0.007097,"amplitude":0.012842},"delay":0,"changeRate":-0.015635395874916795,"floatShares":608000000,"shares":616000000,"eps":2.3240097,"marketStatus":"盘前交易","change":-0.47,"latestTime":"02-13 08:40:49 EST","open":30.05,"high":30.17,"low":29.47,"amount":40832596.17042,"amplitude":0.023287,"askPrice":29.76,"askSize":1000,"bidPrice":29.72,"bidSize":600,"shortable":3,"etf":0,"ttmEps":2.3240097,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1770993000000},"marketStatusCode":1,"adr":0,"adrRate":0.1,"listingDate":1563422400000,"exchange":"NASDAQ","adjPreClose":29.59,"preHourTrading":{"tag":"盘前","latestPrice":29.8,"preClose":29.59,"latestTime":"08:30 EST","volume":8130,"amount":242091.99369,"timestamp":1770989406378,"change":0.21,"changeRate":0.007097,"amplitude":0.012842},"postHourTrading":{"tag":"盘后","latestPrice":30,"preClose":29.59,"latestTime":"19:53 EST","volume":9724,"amount":287792.582,"timestamp":1770944021590,"change":0.41,"changeRate":0.013856,"amplitude":0.013856},"volumeRatio":1.018360222853408,"impliedVol":0.5857,"impliedVolPercentile":0.896},"requestUrl":"/m/hq/s/GMAB/tweets","defaultTab":"tweets","newsList":[{"id":"1103229018","title":"财报前瞻｜Genmab A/S本季度营收预计增16.55%，机构观点偏正面","url":"https://stock-news.laohu8.com/highlight/detail?id=1103229018","media":"财报Agent","labels":["earningPreview"],"top":1,"itemType":null,"share":"https://www.laohu8.com/m/news/1103229018?lang=zh_cn&edition=full","pubTime":"2026-02-10 10:18","pubTimestamp":1770689925,"startTime":"0","endTime":"0","summary":"Genmab A/S将于2026年02月17日发布最新季度财报，市场关注管线商业化规模化与合作版税的韧性，盈利能力与现金流质量或成焦点。市场一致预期本季度Genmab A/S营收预计为10.47亿美元，同比增16.55%；毛利率预计维持高位；净利率与归属母公司净利润暂无一致预测；调整后每股收益预计为0.49美元，同比增75.00%；息税前利润预计为3.85亿美元，同比增44.13%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜Genmab A/S本季度营收预计增16.55%，机构观点偏正面","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GMAB"],"gpt_icon":0},{"id":"2571033097","title":"Genmab进入收购药物开发商Merus的深入谈判阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2571033097","media":"环球市场播报","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2571033097?lang=zh_cn&edition=full","pubTime":"2025-09-29 23:03","pubTimestamp":1759158180,"startTime":"0","endTime":"0","summary":"生物制药公司Genmab （GMAB） 据悉已进入收购荷兰癌症药物开发商Merus （NASDAQ：MRUS） 的深入谈判阶段。今年市值增长60%的Merus预计很快将宣布并购协议。此次收购将增强Genmab的肿瘤产品组合，尽管仍可能出现其他竞标者。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：张俊 SF065","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2025-09-29/doc-infseqec8223133.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["QID","BK4139","TQQQ",".IXIC","SINA","USAW.SI","QLD","GMAB","PSQ","MNQmain","TSYW.SI","NVIW.SI","USJW.SI","SQQQ"],"gpt_icon":0},{"id":"1117767726","title":"Genmab拟斥资80亿美元全现金收购Merus，每股报价97美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1117767726","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1117767726?lang=zh_cn&edition=full","pubTime":"2025-09-29 13:21","pubTimestamp":1759123271,"startTime":"0","endTime":"0","summary":"9月29日，$Genmab(GMAB)$同意以每股97美元的全现金价格收购$Merus(MRUS)$，交易总价值约80亿美元。 美股夜盘时段，Merus大涨近20%，而Genmab则下跌近3%。","market":"us","thumbnail":"https://static.tigerbbs.com/0b841f5eda278b95023e7905323fa0be","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/0b841f5eda278b95023e7905323fa0be"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"484c19b5e334de9a1873457964a50ace","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Genmab拟斥资80亿美元全现金收购Merus，每股报价97美元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4534","BK4588","BK4598","BK4533","BK4516","BK4592","BK4585","BK4551","BK4612","BK4581","BK4604","BK4550","BK4511","BK4574","MRUS","BK4555","BK4527","GMAB","BK4548","BK4543","BK4099"],"gpt_icon":0},{"id":"2564397375","title":"明晟公司MSCI北欧国家指数涨0.6%报345.85点。十个板块中北欧医疗保健板块涨幅最大。生物技术公司Genmab A","url":"https://stock-news.laohu8.com/highlight/detail?id=2564397375","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2564397375?lang=zh_cn&edition=full","pubTime":"2025-09-03 23:38","pubTimestamp":1756913910,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["GMAB","GNMSF","LU0109391861.USD","BK4139","MSCI","LU0320765059.SGD","LU0289960550.SGD","LU0289961442.SGD","LU0511384066.AUD","LU2210149790.SGD","LU1804176565.USD","BK4585","BK4588","LU2210150020.SGD","LU0175139822.USD","LU2265009873.SGD","IE00BKPKM429.USD","LU2095319765.USD","LU1267930730.SGD","LU0672654240.SGD","LU0708995401.HKD","LU0289739343.SGD","BK4112"],"gpt_icon":0},{"id":"2518271854","title":"Genmab As盘中异动 急速下挫6.75%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518271854","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518271854?lang=zh_cn&edition=full","pubTime":"2025-03-10 22:13","pubTimestamp":1741616005,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日22时13分，Genmab As股票出现异动，股价大幅下挫6.75%。Genmab As股票所在的生物技术行业中，整体涨幅为0.21%。Genmab As公司简介：Genmab AS是一家总部位于哥本哈根的生物技术公司，专门从事用于治疗癌症的抗体疗法。Genmab的专有抗体技术是DuoBody、HexaBody、DuoHexaBody和HexElect。强生公司与Genmab公司合作开发了Darzalex，该药物被视为多发性骨髓瘤的标准治疗药物，是Genmab公司的主要产品。Genmab公司还拥有多个针对其他肿瘤适应症的候选药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310221325abf30c0b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310221325abf30c0b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","GMAB"],"gpt_icon":0},{"id":"1171629140","title":"异动解读 | Genmab业绩超预期 股价盘中大涨6.53%","url":"https://stock-news.laohu8.com/highlight/detail?id=1171629140","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1171629140?lang=zh_cn&edition=full","pubTime":"2025-02-14 01:02","pubTimestamp":1739466163,"startTime":"0","endTime":"0","summary":"生物技术公司Genmab A/S(GMAB)今日盘中大涨6.53%,引发市场广泛关注。\n\n消息面上,Genmab公布2024财年业绩,全年营收215.3亿丹麦克朗,超过分析师预期的213.9亿克朗,这一良好业绩成为GMAB股价大涨的主因。\n\n公司简介显示,Genmab是一家总部位于丹麦哥本哈根的生物技术公司,专注于研发用于治疗癌症的抗体疗法。其主要产品包括治疗多发性骨髓瘤的Darzalex、治疗甲状腺眼病的Tepezza等。公司目前还拥有多个治疗其他肿瘤的候选药物在研。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"异动解读 | Genmab业绩超预期 股价盘中大涨6.53%","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["GMAB"],"gpt_icon":0},{"id":"2511655520","title":"【明晟公司MSCI北欧国家指数涨0.6%，报379.67点】明晟公司MSCI北欧国家指数涨0.6%，报379.67点。开发癌症抗体疗法的生物技术公司Genmab A/S涨8.5%，领跑一众成分股。最新业绩报告显示，该公司全年营收215.3亿丹麦克朗，分析师预期213.9亿克朗。","url":"https://stock-news.laohu8.com/highlight/detail?id=2511655520","media":"金融界","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2511655520?lang=zh_cn&edition=full","pubTime":"2025-02-14 00:52","pubTimestamp":1739465543,"startTime":"0","endTime":"0","summary":"明晟公司MSCI北欧国家指数涨0.6%，报379.67点。开发癌症抗体疗法的生物技术公司Genmab A/S涨8.5%，领跑一众成分股。最新业绩报告显示，该公司全年营收215.3亿丹麦克朗，分析师预期213.9亿克朗。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/14005248150518.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["MSCI","GNMSF","GMAB"],"gpt_icon":0},{"id":"2511010521","title":"Genmab As盘中异动 早盘股价大涨5.03%报20.68美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2511010521","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2511010521?lang=zh_cn&edition=full","pubTime":"2025-02-13 23:29","pubTimestamp":1739460567,"startTime":"0","endTime":"0","summary":"北京时间2025年02月13日23时29分，Genmab As股票出现异动，股价快速拉升5.03%。截至发稿，该股报20.68美元/股，成交量68.9807万股，换手率0.11%，振幅3.25%。Genmab As股票所在的生物技术行业中，整体涨幅为0.13%。Genmab As公司简介：Genmab AS是一家总部位于哥本哈根的生物技术公司，专门从事用于治疗癌症的抗体疗法。强生公司与Genmab公司合作开发了Darzalex，该药物被视为多发性骨髓瘤的标准治疗药物，是Genmab公司的主要产品。Genmab公司还拥有多个针对其他肿瘤适应症的候选药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250213232927a244b7ef&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250213232927a244b7ef&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["GMAB","BK4139"],"gpt_icon":0},{"id":"2506148755","title":"Genmab As盘中异动 早盘股价大跌7.88%","url":"https://stock-news.laohu8.com/highlight/detail?id=2506148755","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2506148755?lang=zh_cn&edition=full","pubTime":"2025-01-28 22:31","pubTimestamp":1738074664,"startTime":"0","endTime":"0","summary":"北京时间2025年01月28日22时31分，Genmab As股票出现异动，股价急速下跌7.88%。Genmab As股票所在的生物技术行业中，整体涨幅为0.01%。Genmab As公司简介：Genmab AS是一家总部位于哥本哈根的生物技术公司，专门从事用于治疗癌症的抗体疗法。Genmab的专有抗体技术是DuoBody、HexaBody、DuoHexaBody和HexElect。强生公司与Genmab公司合作开发了Darzalex，该药物被视为多发性骨髓瘤的标准治疗药物，是Genmab公司的主要产品。Genmab公司还拥有多个针对其他肿瘤适应症的候选药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250128223104abbb656c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250128223104abbb656c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","GMAB"],"gpt_icon":0},{"id":"2505478293","title":"Genmab As盘中异动 快速拉升5.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2505478293","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2505478293?lang=zh_cn&edition=full","pubTime":"2025-01-22 04:49","pubTimestamp":1737492596,"startTime":"0","endTime":"0","summary":"北京时间2025年01月22日04时49分，Genmab As股票出现异动，股价急速上涨5.00%。Genmab As股票所在的生物技术行业中，整体涨幅为1.76%。Genmab As公司简介：Genmab AS是一家总部位于哥本哈根的生物技术公司，专门从事用于治疗癌症的抗体疗法。Genmab的专有抗体技术是DuoBody、HexaBody、DuoHexaBody和HexElect。强生公司与Genmab公司合作开发了Darzalex，该药物被视为多发性骨髓瘤的标准治疗药物，是Genmab公司的主要产品。Genmab公司还拥有多个针对其他肿瘤适应症的候选药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250122044956986e737b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250122044956986e737b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","GMAB"],"gpt_icon":0},{"id":"2504449484","title":"特朗普2.0时代即将开启，投资机会如何掘金？","url":"https://stock-news.laohu8.com/highlight/detail?id=2504449484","media":"招商基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2504449484?lang=zh_cn&edition=full","pubTime":"2025-01-20 10:36","pubTimestamp":1737340585,"startTime":"0","endTime":"0","summary":"美国候任总统唐纳德·特朗普将于美东时间1月20日12时正式宣誓就任美国第47任总统。特朗普2.0时代即将开启，有哪些投资机会可以布局？值得一提的是，科技股在特朗普任期内表现尤为突出，成为推动美股上涨的主要力量。在特朗普第一个任期内，美元整体表现相对弱势。4年任期内，美元指数累计下跌了10.53%。而纵观全球市场，在特朗普上一任期内，恒生科技指数涨幅超过147%，表现甚至略微优于纳斯达克指数。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250120103318abb12e8e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250120103318abb12e8e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["FWONK","PAYX","HQY","INSM","TROW","FER","HLNE","LI","NVIW.SI","TRMB","TPG","AEP","LU2065731478.USD","TLN","EQIX","FCNCA","MKTX","CSX","ZS","SOFI","CSCO","BK4581","CDNS","CBSH","ILMN","COIN","LU0053671581.USD","MDLZ","PARA","TCOM","EWBC","MANH","TTEK",".IXIC","RYAAY","DLTR","GRAB","SQQQ","FFIV","INCY","LNW","PLTR","HTHT","COKE","ALAB","MRVL","AMZN","LU1815336091.USD","HBAN","CEG","GLPI","MDB","BKNG","AMAT","FYBR","TXN","CHKP","BK4550","TECH","WWD","QLD","WYNN","ENTG","BKR","LSCC","CDW","ITCI","ADSK","CCEP","NXPI","AZN","TSLA","NBIX","ALGN","BK4086","GMAB","ONC","LNT","ESLT","EA","MNQmain","JKHY","CHRD","HOOD","CHTR","ICLR","HST","BRKR","NDAQ","NWSA","ZM","TEAM","COO","EVRG","WBA","NVMI","TER","AMGN","AGNC","PCTY","CFLT","RKLB","META","EXAS","TSCO","SEIC","TSEM","FOXA","ORLY","NTNX","RADX","DKNG","TTD","NTRA","AFRM","CZR","STX","NICE","CHDN","BK4593","ADI","NVDA","ANSS","ADBE","CTSH","DASH","FTAI","QCOM","AUR","NTES","PSQ","ON","SIRI","EBAY","TQQQ","BPOP","FTNT","BK4534","AVGO","LSTR","CWST","LU0757428866.USD","BSY","ERIE","AAPL","MTSI","INTC","SAIA","OTEX","NDSN","ASML","MSFT","FOX","LULU","CINF","BPMC","NTRS","ROP","ROST","WTFC","KDP","FSLR","QXO","RPRX","AXON","CHRW","SWKS","ODFL","GEHC","AMD","QQQ","MNST","DDOG","PAA","USAW.SI","MKSI","EXPE","DOX","JD","CG","AAL","CPB","PCVX","QID","HON","MIDD","RIVN","Z","AAON","BIIB","BK4561","PNFP","HSIC","MRNA","DOCU","PDD","CYBR","DPZ","NTAP","MTCH","QRVO","ALNY","ENPH","GOOGL","MMYT","MELI","LECO","LOGI","SBUX","NQmain","FAST","BK4588","BMRN","LIN","MARA","MEDP","CTAS","USJW.SI","PFG","POOL","KHC","CSGP","CRWD","EXE","REGN","PCAR","TSYW.SI","BK4585","ERIC","AKAM","LAMR","GTLB","OLED","GILD","CSWI","ROIV","OKTA","CME","CPRT","GEN","DSGX","DUOL","CASY","MPWR","ISRG","PODD","LKQ","APA","ARM","GNTX","JBHT","RGEN","ARGX","IDXX","ROKU","SSNC","TMUS","STLD","MCHP","INTU","SRPT","TTWO","FSV","COST","RGLD","RVMD","SBAC","TW","LPLA","SMCI","FRPT","REG","ULTA","PTC","HOLX","NFLX","SNPS","SFM","MNDY","WDC","PEP"],"gpt_icon":1},{"id":"2504324917","title":"Genmab As盘中异动 快速拉升5.02%报21.25美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2504324917","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2504324917?lang=zh_cn&edition=full","pubTime":"2025-01-17 00:33","pubTimestamp":1737045229,"startTime":"0","endTime":"0","summary":"北京时间2025年01月17日00时33分，Genmab As股票出现异动，股价急速上涨5.02%。截至发稿，该股报21.25美元/股，成交量72.363万股，换手率0.11%，振幅2.67%。Genmab As股票所在的生物技术行业中，整体跌幅为0.39%。Genmab As公司简介：Genmab AS是一家总部位于哥本哈根的生物技术公司，专门从事用于治疗癌症的抗体疗法。强生公司与Genmab公司合作开发了Darzalex，该药物被视为多发性骨髓瘤的标准治疗药物，是Genmab公司的主要产品。Genmab公司还拥有多个针对其他肿瘤适应症的候选药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250117003349a2247bf5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250117003349a2247bf5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","GMAB"],"gpt_icon":0},{"id":"2503640827","title":"Genmab As盘中异动 早盘股价大跌5.82%报20.38美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2503640827","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2503640827?lang=zh_cn&edition=full","pubTime":"2025-01-15 22:31","pubTimestamp":1736951484,"startTime":"0","endTime":"0","summary":"北京时间2025年01月15日22时31分，Genmab As股票出现波动，股价大幅下挫5.82%。截至发稿，该股报20.38美元/股，成交量8.5026万股，换手率0.01%，振幅0.37%。Genmab As股票所在的生物技术行业中，整体涨幅为0.68%。Genmab As公司简介：Genmab AS是一家总部位于哥本哈根的生物技术公司，专门从事用于治疗癌症的抗体疗法。强生公司与Genmab公司合作开发了Darzalex，该药物被视为多发性骨髓瘤的标准治疗药物，是Genmab公司的主要产品。Genmab公司还拥有多个针对其他肿瘤适应症的候选药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250115223124a222fda1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250115223124a222fda1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","GMAB"],"gpt_icon":0},{"id":"2483638585","title":"Genmab As2024财年第三财季实现净利润1.86亿美元，同比减少40.19%","url":"https://stock-news.laohu8.com/highlight/detail?id=2483638585","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483638585?lang=zh_cn&edition=full","pubTime":"2024-11-15 00:01","pubTimestamp":1731600070,"startTime":"0","endTime":"0","summary":"11月15日，Genmab As公布财报，公告显示公司2024财年第三财季净利润为1.86亿美元，同比减少40.19%；其中营业收入为8.16亿美元，同比增加17.92%，每股基本收益为0.29美元。从资产负债表来看，Genmab As总负债11.58亿美元，其中短期债务13.62百万美元，资产负债比为5.13，流动比率为5.18。机构评级：截至2024年11月15日，当前有20家机构对Genmab As目标价做出预测，其中目标均价为36.89美元，其中最低目标价为26.18美元，最高目标价为50.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241115000126a238003b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241115000126a238003b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["GMAB"],"gpt_icon":0},{"id":"2469112856","title":"Genmab As盘中异动 股价大跌5.19%","url":"https://stock-news.laohu8.com/highlight/detail?id=2469112856","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2469112856?lang=zh_cn&edition=full","pubTime":"2024-09-23 21:32","pubTimestamp":1727098320,"startTime":"0","endTime":"0","summary":"北京时间2024年09月23日21时32分，Genmab As股票出现波动，股价大幅下跌5.19%。Genmab As股票所在的生物技术行业中，整体跌幅为0.26%。Genmab As公司简介：Genmab AS是一家总部位于哥本哈根的生物技术公司，专门从事用于治疗癌症的抗体疗法。Genmab的专有抗体技术是DuoBody、HexaBody、DuoHexaBody和HexElect。强生公司与Genmab公司合作开发了Darzalex，该药物被视为多发性骨髓瘤的标准治疗药物，是Genmab公司的主要产品。Genmab公司还拥有多个针对其他肿瘤适应症的候选药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240923213200ab655c41&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240923213200ab655c41&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","GMAB"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.genmab.com","stockEarnings":[{"period":"1week","weight":-0.0446},{"period":"1month","weight":-0.1264},{"period":"3month","weight":-0.0221},{"period":"6month","weight":0.2694},{"period":"1year","weight":0.5028},{"period":"ytd","weight":-0.0393}],"compareEarnings":[{"period":"1week","weight":0.0054},{"period":"1month","weight":-0.018},{"period":"3month","weight":0.0139},{"period":"6month","weight":0.0588},{"period":"1year","weight":0.1291},{"period":"ytd","weight":-0.001}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Genmab A/S于1998年6月11日注册成立。他们是一家国际生物技术公司，专门从事抗体治疗癌症和其他疾病的治疗。他们的核心目的是通过创造和开发创新的抗体产品来改善患者的生活。公司的愿景是通过在2025年推出自己的专利产品来改变癌症治疗方法，并推进其分化和耐受良好的抗体管道。他们正在建设和扩展他们的后期开发和商业能力，以便他们将来可以将他们的专有产品推向市场。","yearOnYearQuotes":[{"month":1,"riseRate":0.285714,"avgChangeRate":-0.047195},{"month":2,"riseRate":0.285714,"avgChangeRate":-0.022586},{"month":3,"riseRate":0.5,"avgChangeRate":-0.012252},{"month":4,"riseRate":0.666667,"avgChangeRate":0.055939},{"month":5,"riseRate":0.5,"avgChangeRate":0.029834},{"month":6,"riseRate":0.5,"avgChangeRate":0.006358},{"month":7,"riseRate":1,"avgChangeRate":0.078593},{"month":8,"riseRate":0.571429,"avgChangeRate":0.046124},{"month":9,"riseRate":0.142857,"avgChangeRate":-0.025366},{"month":10,"riseRate":0.428571,"avgChangeRate":-0.018352},{"month":11,"riseRate":0.714286,"avgChangeRate":0.070997},{"month":12,"riseRate":0.428571,"avgChangeRate":-0.017923}],"exchange":"NASDAQ","name":"Genmab A/S","nameEN":"Genmab A/S"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Genmab A/S(GMAB)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Genmab A/S(GMAB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Genmab A/S,GMAB,Genmab A/S股票,Genmab A/S股票老虎,Genmab A/S股票老虎国际,Genmab A/S行情,Genmab A/S股票行情,Genmab A/S股价,Genmab A/S股市,Genmab A/S股票价格,Genmab A/S股票交易,Genmab A/S股票购买,Genmab A/S股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Genmab A/S(GMAB)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Genmab A/S(GMAB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}